Shire, Barr Resolve Suits Over Generic Adderall

Law360, New York (August 15, 2006, 12:00 AM EDT) -- Shire PLC and Barr Pharmaceuticals have made amends in a long-running patent stand-off over Barr’s efforts to market a copycat version of Shire’s blockbuster hyperactivity drug Adderall.

The companies said Monday that the agreement resolves two pending patent cases in the U.S. District Court for the Southern District of New York. As part of the deal, Barr Laboratories Inc. will not be allowed to market a generic version of Adderall XR in the United States until April 1, 2009.

The two companies clashed for years over...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.